Search results
Results from the WOW.Com Content Network
Intermountain Health (formerly Intermountain Healthcare) is a United States not-for-profit healthcare system with 385 clinics and 33 hospitals in the Intermountain West (primarily Colorado, Idaho, Montana, Nevada, and Utah). The company's headquarters are in Salt Lake City, Utah. Colorado-based SCL Health and Intermountain Health merged in 2022.
Intermountain Primary Children's Hospital (PCH) (formerly Primary Children's Medical Center) is a nationally ranked pediatric acute care children's teaching hospital located in Salt Lake City, Utah. The hospital has 289 pediatric beds [ 2 ] and is affiliated with the University of Utah School of Medicine . [ 3 ]
Park City Hospital (formerly Park City Medical Center) is a full-service community hospital in Park City, Utah, United States.It is located at 900 Round Valley Drive at the northwest corner of Keetley Junction US-40/US-189 and SR-248 (Kearns Boulevard). [1]
Print/export Download as PDF; Printable version; ... Pages in category "Intermountain Health" The following 21 pages are in this category, out of 21 total.
The Orthopedic Specialty Hospital (TOSH) was founded in 1991 and is a 100,000-square-foot (9,300 m 2) facility located in Murray, Utah, United States, at the former Intermountain Healthcare Cottonwood Hospital location. [1]
This cost-spreading mechanism often picks up much of the cost of health care, but individuals must often pay up-front a minimum part of the total cost (a deductible), or a small part of the cost of every procedure (a copayment). Private insurance accounts for 35% of total health spending in the United States, by far the largest share among OECD ...
This total charge data can be converted into cost estimates using the CCR Files, which include hospital-wide values of the all-payer inpatient cost-to-charge ratio for nearly every hospital in the participating NIS, KID, NRD, and SID. The CCR Files are updated annually and available for the HCUP inpatient databases beginning with 2001 data.
In 2016, NICE set the cost-per-QALY threshold at £100,000 for treatments for rare conditions because, otherwise, drugs for a small number of patients would not be profitable. [3] The use of ICERs therefore provides an opportunity to help contain health care costs while minimizing adverse health consequences. [4]